AKLI vs. GETR, LGST, BWAY, KRMD, BLUA, SRTS, HSAQ, ALUR, PDEX, and NSPR
Should you be buying Akili stock or one of its competitors? The main competitors of Akili include Getaround (GETR), Semper Paratus Acquisition (LGST), BrainsWay (BWAY), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), and InspireMD (NSPR).
Akili (NASDAQ:AKLI) and Getaround (NYSE:GETR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.
Akili has higher earnings, but lower revenue than Getaround. Akili is trading at a lower price-to-earnings ratio than Getaround, indicating that it is currently the more affordable of the two stocks.
Getaround has a net margin of -155.92% compared to Akili's net margin of -2,492.04%. Akili's return on equity of -79.93% beat Getaround's return on equity.
In the previous week, Akili had 6 more articles in the media than Getaround. MarketBeat recorded 7 mentions for Akili and 1 mentions for Getaround. Akili's average media sentiment score of 0.23 beat Getaround's score of -0.33 indicating that Akili is being referred to more favorably in the media.
Akili received 3 more outperform votes than Getaround when rated by MarketBeat users. However, 100.00% of users gave Getaround an outperform vote while only 66.67% of users gave Akili an outperform vote.
53.1% of Akili shares are owned by institutional investors. Comparatively, 59.6% of Getaround shares are owned by institutional investors. 10.1% of Akili shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Akili has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Getaround has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Akili currently has a consensus target price of $4.00, indicating a potential upside of 851.02%. Given Akili's higher probable upside, equities research analysts plainly believe Akili is more favorable than Getaround.
Summary
Akili beats Getaround on 12 of the 17 factors compared between the two stocks.
Get Akili News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
